Ardelyx has initiated legal action against the US Department of Health and Human Services and the Centers for Medicare and Medicaid Services (CMS) in response to a decision impacting the payment system for certain medications. The controversy centers on CMS's plan to include Xphozah (tenapanor) and other oral-only phosphate-lowering therapies (PLTs) in the bundled payment system for dialysis patients, effective January 1 of the following year. This adjustment would transition these drugs to the End-Stage Renal Disease Prospective Payment System (ESRD PPS), thus removing their coverage under Medicare Part D.
Ardelyx argues that these medications are not administered at dialysis centers and are unsuitable for use during maintenance dialysis sessions. Consequently, patients rely on outpatient pharmacy benefit plans to access these treatments. To ensure continued patient access to its medication, Ardelyx chose not to apply for the Transitional Drug Add-on Payment Adjustment (TDAPA) earlier this month.
Researching Ardelyx sues CMS over Medicare Part D coverage termination for Xphozah beyond the basics?
Synapse Hiro LS Researcher, the Synapse AI Insight Engine, is built to accelerate biopharma decisions. Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence. Explore Ardelyx sues CMS over Medicare Part D coverage termination for Xphozah with Hiro LS Researcher →
The lawsuit, supported by the American Association of Kidney Patients (AAKP) and the National Minority Quality Forum (NMQF), contends that CMS's decision is likely to significantly and negatively impact patients' ability to choose and access critical medications promptly. According to Mike Raab, the chief executive of Ardelyx, this move will also discourage the development of new medications aimed at addressing unmet needs in a field already lacking sufficient therapeutic options.
Ardelyx has been a robust proponent of bipartisan legislation, known as the Kidney PATIENT Act, which has been introduced in the US Senate. This legislation aims to delay the inclusion of oral PLTs in the ESRD PPS. Analysts at Jefferies have expressed concerns that the uncertainty surrounding Congress's ability to delay the inclusion of oral phosphate binders in the dialysis bundle could negatively affect investor sentiment regarding Xphozah. They estimated a 65% to 75% likelihood of Congress passing the legislation by the end of the year.
Xphozah, which inhibits phosphate absorption through its primary pathway, received approval in the US last year as an add-on therapy for lowering serum phosphorus in dialysis patients who do not respond well or are intolerant to phosphate-binder therapies alone. Raab emphasized that these patients now face the potential loss of access to an FDA-approved therapy that offers them significant clinical benefits.
A FirstWord survey of US nephrologists conducted last year revealed that over 60% of respondents indicated they would consider switching patients to Ardelyx's medication for hyperphosphatemia from their current treatments.
This article provides an overview. For a broader research view, use Synapse Hiro LS Researcher—the Synapse AI Insight Engine—to search across drugs, targets, indications, clinical trials, literature, organizations, news, deals, and competitor signals. Ask any biopharma research question in natural language.
Questions to explore:
Ask Synapse Hiro LS Researcher →
AI may make mistakes. Check important info.
How to obtain the latest development progress of all targets?
In the Synapse database, you can stay updated on the latest research and development advances of all targets. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!